Life Stem Genetics, Inc. (OTCBB:LIFS) announced today a
strategic collaborative agreement with American CryoStem
Corporation, (OTCBB:CRYO). CRYO is a leading developer, marketer
and global licensor of patented adipose tissue-based cellular
technologies for the Regenerative and Personalized Medicine
industries.
Adipose tissue is an anatomical term for loose connective tissue
(fat) composed of adipocytes (cells). It is used in LIFS stem cell
procedures and currently is extracted via liposuction each time a
patient has a treatment. This collaboration will give our
physician’s network the ability to store a patient’s adipose tissue
for future regenerative medicine applications after only one
extraction process. In the absence of future liposuction
procedures, the patient’s recovery time is lessened and additional
procedure costs are reduced.
This collaboration will provide the Company’s physicians and
medical clinics access to a FDA registered laboratory and the
science of tissue collection, processing and long term storage of
their patient’s adipose tissue sample collected at the point of
care.
American CryoStem’s ATGRAFT™ tissue samples are processed and
prepared upon arrival at their FDA registered laboratory based in
Mt. Laurel, N.J., tested for adipocyte and cellular viability, and
stored free of charge for six months. Long term storage fees will
be billed directly to the patient by American CryoStem with revenue
shared with LIFS. Stored patient samples retrieved by LIFS
physicians will be shipped, ready for use without any additional
processing.
Life Stem Genetics Chief Medical Stem Cell Specialist, James
Vanden Bosch, BHA, commented, “This relationship secured with
American CryoStem by Life Stem Genetics advances our physician’s
treatment protocols from traditionally collecting and processing
patients adipose tissue in the same day to establishing a treatment
program not dictated by a single liposuction procedure.” Mr. Vanden
Bosch further commented, “Patients can now visit a clinic and have
future treatments with the same high quality adipose tissue.” he
adds.
The Company expects to begin internal validation of the ATGRAFT™
service in the coming weeks prior to a full roll-out of this new
offering. Additional updates about Life Stem Genetics and American
CryoStem will be announced as this synergistic relationship
continues to develop.
About Life Stem Genetics
Life Stem Genetics ("LSG") is a progressive healthcare company
focused on Adult Stem Cell (ASC) healing therapies. For decades,
stem cells have been utilized in the successful treatment of a
variety of ailments. Today, advanced ASC therapies are being
offered to patients as an efficient and painless alternative
treatment for a wide range of ailments including, but not limited
to, orthopedic injuries, neurological disorders such as Parkinson's
and Alzheimer's, cancer, arthritis, diabetes, multiple sclerosis,
as well as age management. Adult Stem Cell therapies and LSG's
proprietary techniques are experiencing some of the best results in
the industry in helping to repair or reprogram damaged or diseased
tissues and organs. Life Stem's ASC specialist has performed
thousands of stem cell treatments including some of the top names
in PGA golf, NFL football, NBA basketball, and Major League
Baseball. LSG will offer its proprietary treatments through a
series of affiliate doctors and medical clinics with 60 affiliated
clinics thus far. LSG's mission is to develop a comprehensive
approach to the treatment and maintenance of diseases while
breaking free from the medical insurance maze by tapping into an
affordable private-pay sector.
Contrarian Press, an established publisher, has been engaged by
Life Stem Genetics to assist with identification of potential
market participants who may be interested in learning more about
the company and its securities. Updated disclaimer and disclosure
information is available at the publisher's website and at the
following link:
http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
For a copy of LIFS logo is available at:
http://www.lifestemgenetics.com/wp-content/themes/LifeStemGenetics/images/life-stem-genetics-logo.png
About American CryoStem CorporationA pioneer in the
fields of Regenerative and Personalized Medicine, American
CryoStem Corporation is engaged in building a worldwide network
of state-of-the-art clinical laboratories dedicated to processing,
commercial bio-banking and manufacturing cellular applications
using autologous adipose (fat) tissue and Adipose-Derived
Regenerative Cells (ADRCs). The Company maintains a strong,
strategic portfolio of intellectual property, patent applications
and proprietary operating procedural processes that form its
Adipose Tissue Processing Platform, which in turn, supports the
growing pipeline of biologic products and processes, clinical
services and international licensing opportunities. More
specifically, this platform enables the cryopreservation of an
individual's adipose tissue which when needed can be further
clinically processed into Stromal Vascular Fraction (SVF), which
contains ADRCs, other regenerative cells, including white blood
cells, endothelial cells, smooth muscle cells, pericytes,
fibroblasts and pre-adipocytes, among others. Through its ACS
Laboratories division, the Company operates its flagship FDA
registered, cGMP compliant human tissue processing, cryo-storage
and cell culture and differentiation media development facility in
Mount Laurel, New Jersey.
For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
Forward Looking StatementsThis press release may contain
forward-looking statements, including information about
management's view of American CryoStem Corporation’s (“the
Company”) future expectations, plans and prospects. In particular,
when used in the preceding discussion, the words "believes,"
"expects," "intends," "plans," "anticipates," or "may," and similar
conditional expressions are intended to identify forward-looking
statements. Any statements made in this press release other than
those of historical fact, about an action, event or development,
are forward-looking statements. These statements involve known and
unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be
materially different than those expressed or implied in such
statements. Unknown or unpredictable factors also could have
material adverse effects on the Company’s future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and also takes no obligation to
update or correct information prepared by third parties that are
not paid for by American CryoStem Corporation.
This press release contains "forward-looking statements" within
the meaning of the "safe-harbor" provisions of the Private
Securities Litigation Reform Act of 1995 that are not historical
facts. These statements can be identified by the use of
forward-looking terminology such as "believe," "expect," "may",
"could", "estimates", "will," "should," "project," "plan," "seek,"
"intend," or "anticipate" or the negative thereof or comparable
terminology, and include discussions of strategy, and statements
about industry trends and the Company's future performance,
operations, and products. Such statements involve known and unknown
risks, uncertainties and other factors that could cause the
Company's actual results to differ materially from the results
expressed or implied by such statements. Such risks and
uncertainties include, without limitation, market acceptance of the
Company's stem cell therapy treatment program; the Company's
compliance with applicable statutes and regulations: the Company's
reliance on third-party contractors to provide suitable treatment
facilities; the Company's ability to expand its network of
participating clinics and doctors; the Company's ability to develop
an effective marketing strategy; the Company's ability to control
and reduce advertising and marketing costs; the Company's ability
to develop and increase awareness of its brand; the Company's
ability to protect its trademarks; and the success of the Company's
marketing focus to patients, doctors and clinics. For a discussion
of these and other risks and uncertainties see "Risk Factors" and
"Description of Business" in the Company's public filings with the
SEC. Although the Company believes that the expectations reflected
in such forward-looking statements are reasonable, there can be no
assurance that such expectations will prove to be correct. The
Company has no obligation to update the forward-looking information
contained in this press release.
Life Stem GeneticsShareholder Relations,
877-300-6206info@lifestemgenetics.comhttp://www.lifestemgenetics.com/orContrarian
Press, LLCScott Fraser,
Publisher877-300-6205customerservice@contrarianpress.comhttp://contrarianwealthcoalition.com/
Life Stem Genetics (PK) (USOTC:LIFS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Life Stem Genetics (PK) (USOTC:LIFS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
